Lilly earmarks $3B for new European obesity pill factory news2025-11-03T17:58:52+00:00November 3rd, 2025|Endpoints News|
UK regulators look to speed up how rare disease therapies reach the marketnews2025-11-03T17:24:47+00:00November 3rd, 2025|Endpoints News|
Metsera calls Pfizer threats ‘nonsense’ as rift widens between companiesnews2025-11-03T16:46:46+00:00November 3rd, 2025|Endpoints News|
TScan to cut a third of its staff; Iovance advances Amtagvi in lung cancernews2025-11-03T15:43:34+00:00November 3rd, 2025|Endpoints News|
#ASH25: Lilly’s Jaypirca matches Imbruvica in Phase 3 early blood cancer trialnews2025-11-03T14:00:27+00:00November 3rd, 2025|Endpoints News|
#ASH25: Vertex, CRISPR say Casgevy shows promise in younger childrennews2025-11-03T14:00:17+00:00November 3rd, 2025|Endpoints News|
Kimberly-Clark inks $40B+ deal for Kenvuenews2025-11-03T13:52:55+00:00November 3rd, 2025|Endpoints News|
UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessingnews2025-11-03T13:34:28+00:00November 3rd, 2025|Endpoints News|
AstraZeneca, Lilly, Merck contribute $120M to support manufacturing talent in Virginianews2025-11-03T13:19:48+00:00November 3rd, 2025|Endpoints News|
Tempero halts substance use disorder drug, is ‘assessing strategic alternatives’news2025-11-03T12:01:54+00:00November 3rd, 2025|Endpoints News|
